title: Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment.
abstract: OBJECTIVE
  Prolactin elevation has been proposed as a risk factor for low bone density and potentially osteoporosis in patients on long-term treatment with prolactin-elevating antipsychotics. Our objective was to study the acute effects of prolactin elevation on serum markers of bone formation and resorption in patients treated with risperidone.
  
  
  METHODS
  Thirty participants meeting Diagnostic and Statistical Manual of Mental Disorders fourth edition criteria for schizophrenia, major depressive disorder with psychotic features, or bipolar disorder with psychosis were enrolled. At baseline, subjects were antipsychotic free. Subjects were evaluated before and after 4 weeks of risperidone treatment. Assessments included symptom ratings along with testosterone, estradiol, prolactin, osteocalcin (marker of bone formation), and n-telopeptide crosslinks (NTx marker of bone resorption). Primary analysis examined the impact of risperidone treatment on change in the bone markers and hormone levels from pre to post treatment.
  
  
  RESULTS
  Prolactin levels significantly increased from 12.1 ± 1.9 ng/ml to 65.7 ± 12.2 ng/ml after treatment (p < 0.001). NTx markers of bone resorption significantly decreased from 18.31 ± 1.49 nM bone collagen equivalent (BCE) before treatment to 15.50 ± 1.22 nM BCE after treatment in the study sample as a whole (p < 0.05). A trend was observed indicating that NTx may increase in individuals who have the greatest increases in prolactin after treatment r = 0.33, p = 0.07).
  
  
  CONCLUSIONS
  These findings suggest that prolactin elevation is associated with changes in bone physiology very early in the course of treatment with risperidone. Bone resorption decreased in many subjects but higher levels of bone resorption occurred in patients with the greatest increases in prolactin. This may have important implications for prolactin monitoring or the periodic assessment of osteoporosis-related outcomes in patients requiring extended treatment.
authors: University of Illinois at Chicago College of Pharmacy, 833 S. Wood St Rm 164 (M/C 886), Chicago, IL 60612, USA.
authors: Jeffrey R
authors: JR
authors: Bishop
authors: Leah H
authors: LH
authors: Rubin
authors: James L
authors: JL
authors: Reilly
authors: Mani N
authors: MN
authors: Pavuluri
authors: John A
authors: JA
authors: Sweeney
keywords: antipsychotic; bone; prolactin; psychosis; risperidone
references: J Child Adolesc Psychopharmacol. 2010 Dec;20(6):489-93
references: 21186967
references: Psychosom Med. 1995 Sep-Oct;57(5):485-91
references: 8552740
references: Cell Biol Int. 2008 Sep;32(9):1126-35
references: 18556224
references: Adv Exp Med Biol. 1987;219:153-75
references: 3324676
references: Schizophr Bull. 1996;22(3):447-54
references: 8873295
references: J Clin Psychopharmacol. 2005 Feb;25(1):26-31
references: 15643097
references: Endocrinology. 1981 Jan;108(1):83-7
references: 7007025
references: Schizophr Res. 2003 Jan 1;59(1):17-8
references: 12413637
references: Regul Toxicol Pharmacol. 2010 Dec;58(3):360-8
references: 20709132
references: J Clin Psychiatry. 2008 Mar;69(3):385-91
references: 18278991
references: Am J Psychiatry. 2003 Sep;160(9):1618-20
references: 12944336
references: Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:69-82
references: 12650682
references: J Clin Psychopharmacol. 2005 Jun;25(3):259-61
references: 15876906
references: Am J Physiol Endocrinol Metab. 2000 Dec;279(6):E1216-25
references: 11093907
references: Br J Psychiatry. 2004 Jun;184:503-8
references: 15172944
references: Schizophr Res. 2007 Jul;93(1-3):136-43
references: 17467954
references: Bone. 2008 Mar;42(3):535-46
references: 18166509
references: J Psychopharmacol. 2008 Mar;22(2 Suppl):70-5
references: 18477623
references: Neuropsychobiology. 1980;6(1):56-9
references: 6102745
references: Can J Physiol Pharmacol. 1996 Oct;74(10):1157-65
references: 9022836
references: J Clin Psychopharmacol. 2002 Apr;22(2):109-14
references: 11910254
references: Pituitary. 2009;12(2):96-104
references: 18338266
references: J Psychopharmacol. 2008 Mar;22(2 Suppl):12-9
references: 18477617
references: Psychoneuroendocrinology. 2005 Jan;30(1):111-4
references: 15358449
references: Endocr Rev. 2000 Apr;21(2):115-37
references: 10782361
references: Drugs. 2004;64(20):2291-314
references: 15456328
references: Spec Top Endocrinol Metab. 1985;7:237-66
references: 3914097
references: J Cell Biochem. 2009 Jul 1;107(4):677-85
references: 19365811